


PHARMACEUTICAL 2019

OncoMed Pharmaceuticals Inc Rank 71 of 371





PHARMACEUTICAL 2019



OncoMed Pharmaceuticals Inc Rank 71 of 371

The relative strengths and weaknesses of OncoMed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OncoMed Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 404% points. The greatest weakness of OncoMed Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 48%, being 379% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	63,727
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,644
Liabilities, Non-Current	100
Other Assets	728
Other Compr. Net Income	-318
Other Expenses	1,469
Other Liabilities	4,103
Other Net Income	0
Property and Equipment	623
Research and Development	34,443
Revenues	45,983
Selling, General and Administrative Expense	18,172

Output Variable	Value in 1000 USD
Assets	65,078
Liabilities	16,847
Expenses	54,084
Stockholders Equity	48,231
Net Income	-8,101
Comprehensive Net Income	-8,260
Economic Capital Ratio	48%